T. Lively

发表

Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States

Naoko I Simonds, J. Struewing, R. Schilsky, 2018, JCO precision oncology.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Ingrid A Mayer, 2015, The New England journal of medicine.

Criteria for the use of omics-based predictors in clinical trials

Jill P. Mesirov, William L. Bigbee, James H. Doroshow, 2013, Nature.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Jill P Mesirov, Lisa M McShane, James H Doroshow, 2013, BMC Medicine.

Biomarkers in early-phase trials: fundamental issues.

L. McShane, T. Lively, Laura M. Yee, 2018, Bioanalysis.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.

Jacqueline A. Hall, R. Salgado, F. Sweep, 2014, The Lancet. Oncology.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

Igor Jurisica, Kerby Shedden, Steven Eschrich, 2008, Nature Medicine.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Jack Cuzick, Lisa McShane, Christos Sotiriou, 2011, Journal of the National Cancer Institute.

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.

D. Lacombe, S. Litière, S. Hewitt, 2018, Seminars in cancer biology.

Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis

Kelly Y. Kim, B. Sorg, B. Conley, 2017 .

Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2018, The New England journal of medicine.

Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.

J. Olson, M. Ellis, R. Gray, 2020, Journal of the National Cancer Institute.

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

P. Lambin, V. Velculescu, P. Jänne, 2019, European journal of cancer.

Circulating Tumor DNA Assays in Clinical Cancer Research

P. Guan, B. Sorg, B. Conley, 2018, Journal of the National Cancer Institute.

Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use

B. Conley, J. Jessup, T. Lively, 2012, Clinical Cancer Research.

Societal challenges of precision medicine: Bringing order to chaos.

D. Lacombe, J. Martens, U. McDermott, 2017, European journal of cancer.

Translation of Biomarkers into Clinical Practice

L. McShane, H. Makhlouf, T. Lively, 2016 .

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2019, The New England journal of medicine.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

J. Olson, M. Ellis, R. Gray, 2020, JAMA oncology.

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

J. Olson, R. Gray, H. Gómez, 2018, Journal of Clinical Oncology.

Cancer Diagnostics

S. Taube, T. Lively, James W. Jacobson, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

J. Olson, R. Gray, H. Gómez, 2019, Journal of Clinical Oncology.

Challenges in drug and biomarker co-development.

S. Taube, T. Lively, 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

R. Gray, H. Gómez, S. Paik, 2019, General Session Abstracts.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

J. Olson, M. Ellis, R. Gray, 2015, The New England journal of medicine.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

Translating Promising Biomarkers into Oncology Clinical Practice

Michael C Sachs, B. Conley, T. Lively, 2015 .

Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates

J. Olson, R. Gray, T. Whelan, 2023, Cancer Research.